Drug Search Results
More Filters [+]

Vesnarinone

Alternative Names: vesnarinone
Latest Update: 2024-01-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: PDE Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vesnarinone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Sarcoma, Kaposi|HIV Infections

Phase 1: HIV Infections|Acquired Immunodeficiency Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

234D

P2

Completed

Sarcoma, Kaposi|HIV Infections

None

234A

P1

Completed

HIV Infections

None

234B

P1

Completed

Acquired Immunodeficiency Syndrome|HIV Infections

None

234C

N/A

Completed

HIV Infections

None

Recent News Events